A Study of LY2127399 in Participants With Systemic Lupus Erythematosus

NCT01196091 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1164

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupus Erythematosus
Connective Tissue Disease
Autoimmune Disease

Interventions

DRUG: LY2127399
DRUG: Placebo every 2 weeks
DRUG: Placebo every 4 weeks
DRUG: Standard of Care

Sponsor

Eli Lilly and Company